Related Experiment Videos
Insights
Thrombolytic therapy significantly reduces mortality and improves heart function in acute myocardial infarction patients. This treatment, using agents like streptokinase, requires careful monitoring for bleeding complications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy represents a major advancement in treating acute myocardial infarction (AMI).
- Numerous global trials confirm its benefits, including a 50% mortality reduction, decreased infarct size, improved left ventricular function, and reduced heart failure incidence/severity.
Purpose of the Study:
- To review the efficacy and nursing considerations of thrombolytic therapy in acute myocardial infarction.
- To compare the most common thrombolytic agents: streptokinase, tissue plasminogen activator (tPA), and anisoylated plasminogen-streptokinase activator complex (APSAC).
Main Methods:
- Review of recent research trials and clinical guidelines on thrombolytic therapy for AMI.
- Assessment of patient contraindications, potential complications (bleeding, allergic reactions), and reperfusion markers.
- Evaluation of post-therapy management with anticoagulants and antiplatelet agents.
Main Results:
- Streptokinase, tPA, and APSAC demonstrate similar 5-week mortality efficacy when administered intravenously.
- Bleeding complications are the most serious adverse event associated with thrombolytic therapy.
- Nursing care is crucial for patient assessment, monitoring, and management of potential complications.
Conclusions:
- Thrombolytic therapy is a highly effective treatment for acute myocardial infarction, with comparable efficacy among major agents.
- Increased availability of thrombolytic therapy is anticipated, though current US access lags behind Europe.
- Vigilant nursing assessment and management are essential for optimizing patient outcomes and minimizing risks.
Abstract:
Thrombolytic therapy is the most recent advance in the treatment of acute myocardial infarction. Several research trials have been conducted worldwide in the last decade that have established that thrombolytic therapy has reduced mortality 50%, reduces the size of the infarction, improves left ventricular function, and reduces the incidence and severity of congestive heart failure. The three most commonly used thrombolytic agents at this time are streptokinase, tissue plasminogen activator, and anisoylated plasminogen-streptokinase activator complex. All three agents can be administered through a peripheral intravenous. Recent research results have reported similar efficacy on 5-week mortality of all three agents. Careful assessment of prospective patients is essential since bleeding complications are the most serious side effect of this therapy. Nursing care of a patient undergoing thrombolytic therapy includes careful assessment of the patient for contraindications in the patient's medical history, assessment of potential allergic and bleeding complications, and evaluation of the reperfusion markers. Patients are subsequently treated with anticoagulants, aspirin, or dipyridamole. It appears that thrombolytic therapy will become increasingly available to all patients with a diagnosis of suspected acute myocardial infarction. At present, treatment with thrombolytic agents is less available in the United States compared to Europe.